Literature DB >> 18460342

Rho GTPases in cancer cell biology.

Francisco M Vega1, Anne J Ridley.   

Abstract

Rho GTPases contribute to multiple cellular processes that could affect cancer progression, including cytoskeletal dynamics, cell cycle progression, transcriptional regulation, cell survival and vesicle trafficking. In vitro several Rho GTPases have oncogenic activity and/or can promote cancer cell invasion, and this correlates with increased expression and activity in a variety of cancers. Conversely, other family members appear to act as tumour suppressors and are deleted, mutated or downregulated in some cancers. Genetic models are starting to provide new information on how Rho GTPases affect cancer development and progression. Here, we discuss how Rho GTPases could contribute to different steps of cancer progression, including proliferation, survival, invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460342     DOI: 10.1016/j.febslet.2008.04.039

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  332 in total

1.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

2.  High-throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors.

Authors:  Zurab Surviladze; Susan M Young; Larry A Sklar
Journal:  Methods Mol Biol       Date:  2012

3.  Expanding applications of chemical genetics in signal transduction.

Authors:  Scott M Carlson; Forest M White
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

4.  Cells lacking β-actin are genetically reprogrammed and maintain conditional migratory capacity.

Authors:  Davina Tondeleir; Anja Lambrechts; Matthias Müller; Veronique Jonckheere; Thierry Doll; Drieke Vandamme; Karima Bakkali; Davy Waterschoot; Marianne Lemaistre; Olivier Debeir; Christine Decaestecker; Boris Hinz; An Staes; Evy Timmerman; Niklaas Colaert; Kris Gevaert; Joël Vandekerckhove; Christophe Ampe
Journal:  Mol Cell Proteomics       Date:  2012-03-22       Impact factor: 5.911

5.  A directed miniscreen for genes involved in the Drosophila anti-parasitoid immune response.

Authors:  Laura Howell; Christopher J Sampson; Miguel J Xavier; Ekin Bolukbasi; Margarete M S Heck; Michael J Williams
Journal:  Immunogenetics       Date:  2011-09-27       Impact factor: 2.846

6.  Extracellular signal-regulated kinase and GEF-H1 mediate depolarization-induced Rho activation and paracellular permeability increase.

Authors:  Faiza Waheed; Pam Speight; Glenn Kawai; Qinghong Dan; András Kapus; Katalin Szászi
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-17       Impact factor: 4.249

Review 7.  The Rho guanine nucleotide exchange factors Intersectin 1L and β-Pix control calcium-regulated exocytosis in neuroendocrine PC12 cells.

Authors:  F Momboisse; S Ory; M Ceridono; V Calco; N Vitale; M-F Bader; S Gasman
Journal:  Cell Mol Neurobiol       Date:  2010-11-19       Impact factor: 5.046

Review 8.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

9.  Rac-dependent doubling of HeLa cell area and impairment of cell migration and cell cycle by compounds from Iris germanica.

Authors:  Michal Halpert; Mohamad Abu-Abied; Dror Avisar; Yoni Moskovitz; Osnat Altshuler; Avner Cohen; Mira Weissberg; Joseph Riov; Hugo E Gottlieb; Avichai Perl; Einat Sadot
Journal:  Protoplasma       Date:  2011-01-05       Impact factor: 3.356

10.  Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

Authors:  Tomoyo Okada; Ann Y Lee; Li-Xuan Qin; Narasimhan Agaram; Takahiro Mimae; Yawei Shen; Rachael O'Connor; Miguel A López-Lago; Amanda Craig; Martin L Miller; Phaedra Agius; Evan Molinelli; Nicholas D Socci; Aimee M Crago; Fumi Shima; Chris Sander; Samuel Singer
Journal:  Cancer Discov       Date:  2016-08-30       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.